Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCARDIA XL vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
30-90 mg orally once daily, extended-release tablet.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Hepatic metabolism primarily via CYP3A4
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
92-98% bound primarily to albumin.
Approximately 90% bound to plasma proteins, primarily albumin.
0.78-1.6 L/kg; high Vd indicates extensive tissue distribution.
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Oral (extended-release): 65-85% due to first-pass metabolism; absolute bioavailability 45-65%.
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
No specific dose adjustment for GFR; use with caution in renal impairment due to potential accumulation of metabolites.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Child-Pugh A and B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Safety and efficacy not established; use not recommended.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
Start at lowest dose (30 mg daily) and titrate slowly; monitor for hypotension and peripheral edema.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
Increased risk of cardiovascular events and mortality in patients with coronary artery disease when using short-acting nifedipine; use with caution.
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
May cause severe hypotension, especially in patients on beta-blockers,Can exacerbate angina or cause myocardial infarction upon initiation or dose increase,Peripheral edema is common and dose-dependent,Avoid grapefruit juice which increases nifedipine levels,Use caution in patients with hepatic impairment
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin) due to decreased efficacy
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Avoid grapefruit and grapefruit juice. Grapefruit inhibits CYP3A4, increasing nifedipine plasma concentrations and risk of toxicity. High-fat meals may slightly increase absorption but no specific restriction.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
In animal studies, nifedipine caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies, phalangeal malformations) at doses 30-100 times the maximum recommended human dose. In humans, no adequate controlled studies; however, case reports and observational studies suggest an increased risk of preterm birth and possibly fetal distress after third-trimester use. Use in the first trimester is associated with possible cardiovascular defects. Avoid in pregnancy unless benefit clearly outweighs risk.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Nifedipine is excreted into breast milk in concentrations similar to maternal plasma (M/P ratio approximately 1.0). In clinical studies, no adverse effects in nursing infants have been reported, but caution is advised, especially in neonates with compromised cardiac function.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
No specific dosing adjustments are recommended for nifedipine in pregnancy. However, due to increased volume of distribution and hepatic blood flow in pregnancy, lower trough levels may occur; clinical response and tolerability should guide dosing. Use immediate-release with caution in preterm labor; sustained-release formulations preferred for chronic hypertension.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
PROCARDIA XL (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid grapefruit juice due to CYP3A4 inhibition increasing nifedipine levels. Do not crush or chew tablets; swallow whole. Monitor for peripheral edema, especially in elderly. Use with caution in patients with severe aortic stenosis or heart failure with reduced ejection fraction. Abrupt discontinuation may cause rebound hypertension.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Take exactly as prescribed, usually once daily.,Swallow tablet whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving until you know how you react.,Do not stop taking without consulting your doctor; sudden stop may worsen blood pressure.,Report swelling in ankles/feet, persistent cough, or irregular heartbeat.,Keep tablets in original container; protect from light and moisture.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCARDIA XL vs CALAN, answered by our medical review team.
PROCARDIA XL is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCARDIA XL and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCARDIA XL is: 30-90 mg orally once daily, extended-release tablet.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCARDIA XL and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCARDIA XL is classified as Category C. In animal studies, nifedipine caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies, phalangeal malformations) at doses 30-100 times the maximum recommended h. CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.